Abstract Coronavirus disease 2019 (COVID‐19) is an ongoing pandemic, which affected
around 45 million confirmed cases of COVID‐19, including more than 6 million deaths …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

Background Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …

VE was significantly higher among patients who received their second mRNA COVID-19
vaccine dose< 180 days before medical encounters compared with those vaccinated≥ 180 …

Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …

Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective …

Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE)
against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal …

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized …

The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome …